Improving nelarabine efficacy in refractory/relapsed T-cell acute lymphoblastic leukemia (T-ALL) by targeting aberrant PI3K/mTOR signaling. (July 2016) - Chiarini, F.; Cappellini, A.; Lonetti, A.; Bertaina, A.; Locatelli, F.; Melchionda, F.; Pession, A.; Martelli, A.M.